Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine niche and are considered stock leaders.
6 reports, 2 independent
Updated Aug 14
Gone quiet
- Reports
- 6
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine niche and are considered stock leaders.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Hims & Hers and Eucalyptus expand internationally through a partnership granting access to branded GLP-1 medications.Sub-event
Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine market.1 source
Companies are intensifying competition in the weight loss drug market, with Amgen also expanding its rare disease business.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Amgen
American multinational biopharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.